Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
$156.35
-$0.23(-0.27%)
At close: 4:00 PM EST
$156.35
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$86.99 - $191.50
Previous CloseN/A
Volume140.83K
Average Volume (3M)597.77K
Market Cap
$8.21B
Enterprise Value$8.13B
Total Cash (Recent Filing)$322.93M
Total Debt (Recent Filing)$241.29M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 11, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding51,153,290
10 Day Avg. Volume584,035
30 Day Avg. Volume597,771
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)102.90
Price to Sales (P/S)14.23
P/FCF Ratio-97.27
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue12.73
Enterprise Value/Gross Profit13.75
Enterprise Value/Ebitda-48.82
Forecast
1Y Price Target
$224.85Price Target Upside43.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$987.95M
Bulls Say, Bears Say
Bulls Say
Commercial Infrastructure And Payer CoverageSubstantial expansion of the field sales force combined with improving payer coverage and established commercial footprint provides a ready infrastructure to support broader launches and higher product uptake.
Prescription MomentumSteady and stronger-than-expected prescription gains for Auvelity and Symbravo across multiple data sources suggest ongoing market adoption that could support continued sales growth.
Regulatory Approval PotentialA potential label expansion into an Alzheimer's agitation indication is under regulatory review and strong pivotal data have led analysts to view approval as likely, which could materially boost revenue if granted.
Bears Say
Competitive PressureAuvelity lagging several antidepressant and atypical antipsychotic peers on prescription growth signals competitive pressure that could limit market share gains in key treatment categories.
Early Launch Headwinds And GTN DeductionsLimited early revenue from the second product and Symbravo due to high gross-to-net deductions from copay assistance and constrained payer coverage may restrain near-term contribution to overall sales.
Rising Operating CostsHigher operating expenses driven by expanded commercialization efforts and national advertising contributed to a modest bottom-line miss, increasing execution risk on profitability.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $86.99 and its highest was $191.50 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $8.21B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is May 11, 2026 which is in 40 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Feb 23, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.694 by $0.134.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -0.79.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 51,153,290 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.694. Following the earnings report the stock price went down -4.877%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$224.85 (43.81% Upside)
$224.85 (43.81% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.39%
12-Months-Change
Fundamentals
Return on Equity
-254.14%
Trailing 12-Months
Asset Growth
21.34%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and robust pipeline progress: substantial year-over-year revenue growth (+65% Q4, +66% full year), breakout performance of Auvelity (surpassing $500M annual sales in year three), multiple upcoming clinical readouts and regulatory milestones (Auvelity sNDA priority review, imminent AXS-12 NDA, several Phase III starts), and strategic in-licensing (AXS-17). Offsetting factors include expanding gross-to-net discounts (pressuring net realizations), a sizable increase in SG&A to fund commercialization and DTC, modest early Cymbravo sales with high launch discounts, and some clinical enrollment timing delays. Overall, the positives (strong top-line growth, product momentum, regulatory progress and pipeline breadth) materially outweigh the challenges, leading to a constructive outlook.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$224.85
▲(43.81% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
15.47% Insiders
24.86% Mutual Funds
21.25% Other Institutional Investors
25.39% Public Companies and Individual Investors